The adoptive transfer of cytotoxic T lymphocytes (CTLs) derived from tumor-infiltrating lymphocytes (TIL) along with interleukin 2 (IL-2) into autologous patients with cancer resulted in the objective regression of tumor, indicating that these CTLs recognized cancer rejection antigens on tumor cells. To understand the molecular basis of T cell-mediated antitumor immunity, several groups started to search for such tumor antigens in melanoma as well as in other types of cancers. This led to the subject I will review in this article. A number of tumor antigens were isolated by the use of cDNA expression systems and biochemical approaches. These tumor anti-
INTRODUCTION
The immune system plays a critical role in immunosurveillance against cancer and in tumor regression. The importance of T cells in the regression of tumors has been demonstrated in experimental animal tumor models (1) (2) (3) . Adoptive transfer of tumor-infiltrating lymphocytes (TIL) along with interleukin-2 (IL-2) into the autologous patients resulted in the objective regression of tumor (4, 5) . To antigens in the past few years. These studies have provided the basis for understanding T cell-mediated antitumor activity, and a rationale for the development of anticancer vaccines. Clinical trials using peptides derived from the identified tumor antigens have shown promising results in the treatment of patients with melanoma. Recombinant viruses expressing tumor antigens combined with cytokines and costimulatory molecules are being evaluated for the potential therapeutic effect.
APPROACHES TO IDENTIFICATION OF HUMAN TUMOR ANTIGENS

Genetic Approach
The first approach is to transfect recombinant genomic DNA or cDNA libraries into cells expressing the appropriate MHC molecule. This system was recently improved by the use of cDNA libraries that are transfected transiently into COS or 293 cells along with a cDNA encoding the appropriate MHC molecule (6, 7) . Positive clones are identified on the basis of the ability to stimulate cytokine release from CTL. This simple and powerful approach has led to the identification of many genes encoding tumor antigens (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . Major drawbacks of this approach include the possibility of identifying cDNA clones that encode cross-reacting peptides recognized by T cells due to a high expression level in COS system, and the need to identify the antigenic peptides from the amino acid sequence of the antigenic proteins.
Peptide Isolation T cells recognize a peptide bound to the MHC class I molecule. Tumor-specific peptides can be eluted with acid from either the tumor cell surface or purified peptide-MHC complexes, and they can be separated subsequently by highpressure liquid chromatography (HPLC). The eluted peptide fractions are then tested for their ability to stimulate cytokine secretion from CTL when pulsed onto MHC-matched antigen-presenting cells (APC) . If the amount of peptide in the positive fraction is sufficient to allow sequence determination by Edman degradation, a naturally processed, tumor-specific peptide recognized by CTL can be directly identified (17) . The peptide sequence can then be used to search databases to find the gene encoding the antigenic peptide. Drawbacks to this approach include the technical complexities associated with fractionation of the active peptides and the use of instruments such as tandem mass spectrometry.
It is worth noting that synthetic peptide libraries based on the peptide binding motif of a particular MHC molecule have been used for identification of an antigenic peptide recognized by CTL (18) . However, the identified peptide may be a cross-reactive peptide, rather than an authentic peptide derived from a tumor antigen.
"Reverse Immunology" Approach
In some cases, no tumor-reactive CTL exists. For example, it is relatively difficult to generate breast tumor-reactive CTL from a patient, but there is a putative tumor antigen whose expression is known to be associated with tumor (19, 20) . To prove that this is a true tumor antigen, it is necessary to generate CTLs in vitro using peptides derived from a putative tumor antigen (19) (20) (21) (22) (23) (Table 1) . Thus, they may represent tumor rejection antigens. These antigens were expressed in melanoma, normal melanocytes, and retina, but not in other normal human tissues. TYROSINASE. Tyrosinase is the first member of differentiation antigens identified and is an important enzyme involved in the synthesis of melanin (6, 25) . Two distinct epitopes, MLLAVLYLL and YMNGTMSQV, were identified from the tyrosinase molecule and recognized by CTLs in the context of HLA-A2 (26) . The tyrosinase antigen was also shown to be recognized by an HLA-A24-restricted TIL888 that had been previously shown to result in the regression of multiple metastatic lesions when adoptively transferred into the autologous patient along with IL-2 (12). In addition, the peptide SEIWRDIDF derived from the tyrosinase protein was recognized by HLA-B44-restricted T cells (27) . Interestingly, a naturally processed HLA-A2-associated peptide YMDGTMSQV was identified by peptide elution and mass spectrometry. This peptide results from the post-translational conversion of asparagine (29, 30, 34) . Studies directed toward identifying MHC class II-restricted tumor antigens are currently in progress.
MART-1/MELAN-A. The MART-I gene was isolated by screening of a melanoma cDNA library with the HLA-A2-restricted melanoma-reactive TIL 1235 (35) . MART-1 is identical to Melan-A independently cloned by another group (7) . The MART-1 cDNA isolated from melanoma cells did not contain any mutation or other alterations in the coding region. Northern blot analysis indicated that MART-I was expressed only in melanomas, melanocytes, and retina, but not in normal human tissues (35) . The MART-1 gene product was found to be an immunodominant melanoma antigen recognized by the majority of HLA-A2-restricted melanoma-reactive CTL established from TIL in the Surgery Branch, NCI (35, 36) , as well as a large percentage of melanoma reactive clones derived from the peripheral blood lymphocytes (PBL) of HLA-A2+ melanoma patients (37) . One 9-mere peptide, AA GIGELTV (M9-27), was found to be recognized by HLA-A2-restricted melanoma-specific CTL (36) . Although MART-1 is a dominant antigen recognized by many HLA-A2-restricted TIL, no correlation was found between T cell recognition of MART-1 and clinical response. In contrast, a strong correlation was found between the T cell recognition of gplO0 and clinical response (38) . Some TILs recognize both MART-1 and gplOO (38) . GP 100. A cDNA clone encoding gplOO was isolated and shown to be almost identical to Pmell 7, which had previously been cloned using anti-melanoma antibodies (39) (40) (41) . Northern blot analysis demonstrated that gplOO was expressed in neonatal cultured melanocyte lines, most melanoma cell lines, and retina, but not in other normal tissues (40) . The gplOO molecule was found to be recognized by 8 out of 21 HLA-A2-restricted melanoma-reactive TIL established from different patients with melanoma in the Surgery Branch, NCI, and appears to represent a highly immunogenic antigen. Some CTL lines can recognize multiple gp 100 epitopes. Many gplOO epitopes have been identified by CTLs derived from different patients (38, 40, 42) . Recently, a HLA-A3-restricted epitope was identified from the normal coding sequence of gplOO (43) .
One of the gp 100 epitopes, YLEPGPVTA, was independently isolated from an HPLC-purified fraction of peptides obtained from HLA-A2-positive melanoma (44) . This observation validates both genetic and biochemical approaches to the identification of naturally processed peptides on tumor cells. TRP-11GP75. While all antigenic peptides discussed above were identified from the normal open reading frame, T cells are also capable of recognizing antigenic peptides from an alternative open reading frame or an intron of an mRNA transcript (Table 1) . Several examples have recently been reported.
Previous studies showed that TIL586 derived from patient 586 recognized one or more antigens in the context of HLA-A31 (45) . A tumor antigen encoded by TRP-1 /gp75 was isolated following cDNA library screening. Interestingly, gp75 was previously reported to be recognized by IgG antibodies in the serum of a patient with melanoma (46) . Northern blot and protein analysis indicated that the gp75 protein was one of the most abundant intracellular glycoproteins in melanocyte-lineage cells, but it was not detected in non melanocytic cell types (45, 47, 48) . The gp75 molecule has recently been shown to have DHI-2-carboxylic acid oxidase activity involved in the synthesis of melanin (49) . To identify the epitope in gp75, DNA deletion constructs were made to localize an antigenic peptide to a small DNA fragment. A number of peptides were synthesized on the basis of the predicted amino acid sequence of gp75 and the peptide binding motif for HLA-A31 (50) . None of the peptides tested were found to stimulate cytokine release from TIL586 when pulsed onto HLA-A31 -positive EBV-transformed B cells (51) . However, two ATG start codons were present in different open reading frames relative to the normal gp75 ORFI reading frame (Fig. 1) . To explore this possibility, three peptides derived from ORF2 and two peptides from ORF3 were selected and synthesized on the basis of the HLA-A31 binding motif. Surprisingly, the peptide MSLQRQFLR, which was derived from ORF3, was capable of stimulating cytokine release from TIL586 when pulsed onto HLA-A31 -positive EBV-transformed B cells ( Fig. 2) Tumor-Specific Unique Antigens Many mutations have been identified from tumor suppressor genes such as ras, p53, and p16 tumor samples. Because the mutated proteins or peptides could be more immunogenic and be seen as foreign by the host immune system, it has long been assumed that many tumor antigens would be mutated antigens recognized by T cells. Surprisingly, the majority of tumor antigens identified are nonmutated self-proteins. To test whether mutated ras and p53 are tumorspecific antigens, several groups have raised CTLs against normal or mutated peptides from the ras proto-oncogene (67) and p53 tumor suppressor gene (19, (68) (69) (70) (71) . However, in most cases these CTLs failed to recognize tumor cells. One possibility is that peptides selected on the basis of peptide-binding motif are not naturally processed or that the density of MHC-peptide complexes is too low on tumor cells to allow recognition by these CTLs. It should be noted, however, that despite the numerous mutations identified in ras and p53, only a very small subset of mutations enhance, if they are processed, the MHC-binding affinity or T cell recognition. Several mutated gene products have been recently identified as tumor-specific antigens recognized by CTL derived from patients by screening cDNA libraries using reactive CTLs (Table 3) .
MUM-1 (melanoma-ubiquitous mutated) was isolated following the transient transfection of COS cells with HLA-B44 and pools of cDNAs The mutated ,3-catenin gene product was also recently identified and shown to be recognized by TIL1290 derived from a melanoma patient 888 (15) . Partial cDNA sequence analysis indicated that a point mutation was found to be responsible for a change of serine to phenylalanine in the coding region. The mutated f3-catenin peptide SYLDSGIHF was found to actively sensitize target cells for lysis at a concentration of 1 pM, whereas the normal peptide (SYLDSGIHS) required a much higher peptide concentration to sensitize lysis of target cells. A competitive peptide binding assay indicated that this substitution resulted in an increase in binding affinity of the mutated peptide to the HLA-A24 molecule. The ,B-catenin protein has been shown to be a cytoplasmic protein that interacts with the cellular adhesion molecule E-cadherin (73) . A number of mutations have been found in the ,B-catenin gene product from different tumors (74, 75) . Loss of cell adhesion molecules may play a role in the metastatic process (76) . Recently, three groups reported that the upregulation or stabilization of ,B-catenin may contribute to tumorigenesis and cancer progression because of mutations in the adenomatous polyposis coli tumor suppressor protein (APC) or f3-catenin (77-79).
An HLA-A2 mutation was found to be recognized in renal carcinoma cells by CTL. Interestingly, T cells recognized the mutated whole HLA-A2 molecule, instead of recognizing the mutated peptide epitope (80) .
Tumor Antigens Ubiquitously Expressed
The majority of human melanoma antigens identified thus far are tissue-specific. However, one melanoma-specific T cell line was found to recognize an antigen termed p1 5, whose expression is ubiquitous in normal tissues (81) . A nonmutated peptide, AYGLDFYIL, was identified as a T cell epitope derived from the p15 protein. It is not clear whether this peptide represents a true T cell epitope or is a cross-reactive one with the product derived from an unknown gene but is still recognized by TIL1290 on tumor cells. The low level of expression of this antigen in normal tissues may not generate a sufficient amount of MHC-peptide complex on the cell surface to elicit a T cell response.
HER-2/neu was recently identified as a shared tumor antigen recognized by T cells in breast and ovarian cancers. The HER-2/neu proto-oncogene encodes a tyrosine kinase protein whose expression has been shown to be increased in 30% of breast and ovarian cancers. In breast cancer, HER-2/neu overexpression was reported to be associated with aggressive disease. Cytotoxic T lymphocytes isolated from tumorassociated lymphocytes can specifically recognize a synthetic peptide corresponding to amino acids 971-980 of the HER-2/neu protein (82) . This is the first demonstration that CTLs isolated from human tumors recognize HER-2/neu as an ovarian tumor antigen. Recently, four ovarian tumor-reactive CTLs were established from different HLA-A2 + patients and were capable of recognizing both freshly isolated HER-2/neu+ tumor cells and non-HLA-A2 ovarian tumor lines transfected with HLA-A2 cDNA (20) . A common epitope, KIFGSLAFL, was found to be recognized by four of four CTL lines (20) . Another epitope peptide (971-980) was also found to be recognized by two of four CTL lines. These results were supported by findings of other groups (83, 84) . Recognition and lysis of ovarian cancer cells by CTLs were also shown to correlate with the expression level of HER-2/neu in the tumor cells (83) . Most importantly, the breast and ovarian cancer-specific CTLs recognized the same epitope peptide (GP2; amino acids 654-662) derived from the HER-2/neu protein in the context of HLA-A2 (85, 86) . It appears that the GP2 peptide represents a common epitope shared by different epithelial tumors because it was recognized by CTL lines derived from breast, ovarian, non-small-cell lung and pancreatic cancers (86) .
Another tumor antigen in this class is the mucin-associated epitope from the muc-1 gene product, whose expression has been shown to be associated with breast and pancreatic adenocarcinomas (87) . The muc-1 gene is expressed on epithelial cells, fibroblasts, and B cells, and it can serve as a target for T cell recognition. However, T cell recognition of the muc-1 gene product appeared to be non-MHC restricted (88) . The epitopes for T cell recognition were found in the tandem repeat of the muc-1 protein (89).
PERSPECTIVES FOR CANCER THERAPIES
The identification of tumor antigens recognized by T cells has important implications in the understanding of T cell-mediated antitumor activity and provides opportunities for the development of new strategies for cancer vaccines. Because the majority of tumor antigens identified thus far are self-proteins, a potential consequence of active immunization with these cancer peptides is the development of autoimmune disease (90, 91) . Development of vitiligo has been found to be correlated with good prognosis or clinical responses to immunochemotherapy in mela-noma patients (92) (93) (94) . The adoptive transfer of autologous TIL along with IL-2 into patients with melanoma resulted in the objective regression of tumor, but only occasionally resulted in the depigmentation of skin in treated patients, suggesting that the treatment of patients with anti-self T cells does not necessarily cause tissue destruction in normal organs (40, 45) . Patients developed neither depigmentation nor any retinal tissue destruction after treatment with tyrosinase-specific TILs (95) . Recently, Houghton and co-workers have demonstrated that passive immunization with a mouse monoclonal antibody (TA99) against gp75 induced protection against and rejection of the gp75+ B16F1O melanoma in syngeneic mice (96 
